HepaStem
DrugHeterologous human adult liver-derived progenitor cells
NCT Number: NCT03963921
Multicenter, open-label, safety and tolerability study of ascending doses of HepaStem in patients with cirrhotic and pre-cirrhotic non-alcoholic steato-hepatitis (NASH) to determine the safety and tolerability of ascending single and repeated doses of HepaStem administered to patients with cirrhotic and pre-cirrhotic non-alcoholic steato-hepatitis (NASH)
Looking for future studies?
Notify Me18 year–70 year
All sexes
Interventional
Phase 1 / Phase 2
CUB Erasme, Brussels, Belgium
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Main Inclusion Criteria:
Main Exclusion Criteria:
Heterologous human adult liver-derived progenitor cells
Time frame: up to Day 28
Safety and Tolerability
Cellaion SA
Industry
Multicenter, Open-label, Safety and Tolerability Study of Ascending Doses of HepaStem in Patients With Cirrhotic and Pre-cirrhotic Non-alcoholic Steato-hepatitis (NASH)
Acronym: PANASH
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05039450
Digestive System Diseases, Fatty Liver
Chandler, Arizona, United States
View Trial DetailsNCT05338034
Digestive System Diseases, Fatty Liver
Texas City, Texas, United States
View Trial DetailsNCT06195943
Behavior, Digestive System Diseases
Hershey, Pennsylvania, United States
View Trial DetailsNCT04591106
Digestive System Diseases, Fatty Liver
Los Angeles, California, United States
View Trial Details